Bioventus Inc - Class A

Research Bioventus Inc - Class A (BVS) on Bullrun: valuation model: 3.2% overvalued, market cap USD 891.19M, P/E 16.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerBVS
ExchangeNASDAQ
CountryUnited States
SectorHealthcare
IndustryMedical Devices
CurrencyUSD
Valuation signal3.2% overvalued
Market capUSD 891.19M
P/E16.8
Financial periodQ2 2026
RevenueUSD 153.21M
Net incomeUSD 33.44M
Free cash flowUSD 18.91M
Gross margin69.0%

Valuation Snapshot

Bullrun's latest valuation model marks Bioventus Inc - Class A as 3.2% overvalued; latest market cap is USD 891.19M; P/E is 16.8.

Peer valuation comparison

Latest P/E is 16.85x versus a Healthcare sector median of 24.64x (31.6% below).

Latest P/E is 16.85x versus a United States median of 23.85x (29.4% below).

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	USD 568.09M	USD 22.73M	USD 72.11M	68.3%	0.33	USD 51.24M	USD 293.95M	USD 184.11M
FY2024	USD 573.28M	-USD 36.13M	USD 37.79M	67.7%	-0.56	USD 41.58M	USD 335.63M	USD 147.94M
FY2023	USD 512.35M	-USD 156.23M	USD 7.98M	64.1%	-2.49	USD 36.96M	USD 394.85M	USD 173.59M
FY2022	USD 512.12M	-USD 158.70M	-USD 15.02M	64.6%	-2.59	USD 30.19M	USD 418.07M	USD 325.24M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-09	USD 891.19M	16.8	n/a	n/a
2025	2025-12-31	USD 499.21M	22.5	n/a	n/a
2024	2024-12-31	USD 690.46M	n/a	n/a	n/a
2023	2023-12-29	USD 331.83M	n/a	n/a	n/a
2022	2022-12-30	USD 161.69M	n/a	n/a	n/a
2021	2021-12-31	USD 862.86M	30.8	n/a	n/a

About Bioventus Inc - Class A

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis;

Related stock research

United States stocks United States Healthcare stocks A-Z stock index

Other Healthcare stocks

Abbott Laboratories (ABT) Adagio Medical Holdings Inc (ADGM) Aethlon Medical Inc (AEMD) AdaptHealth Corp (AHCO) Alamar Biosciences, Inc. (ALMR) Allurion Technologies Inc (ALUR) Autonomix Medical Inc (AMIX) Artivion Inc (AORT) AOTI Inc (AOTI) Apyx Medical Corp (APYX) Accuray Inc (ARAY) Alphatec Holdings Inc (ATEC)

Frequently asked questions

Is Bioventus Inc - Class A overvalued or undervalued?

Bullrun's valuation model currently marks Bioventus Inc - Class A as 3.2% overvalued.

What is Bioventus Inc - Class A's market cap?

Bioventus Inc - Class A's market capitalization is USD 891.19M.

What is Bioventus Inc - Class A's P/E ratio?

Bioventus Inc - Class A's price-to-earnings (P/E) ratio is 16.8.

What does Bioventus Inc - Class A do?

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.